Show simple item record

dc.contributor.authorCryan, Jane B.en_US
dc.contributor.authorHaidar, Samen_US
dc.contributor.authorRamkissoon, Lori A.en_US
dc.contributor.authorBi, Wenya Lindaen_US
dc.contributor.authorKnoff, David S.en_US
dc.contributor.authorSchultz, Nikolausen_US
dc.contributor.authorAbedalthagafi, Malaken_US
dc.contributor.authorBrown, Lorealen_US
dc.contributor.authorWen, Patrick Y.en_US
dc.contributor.authorReardon, David A.en_US
dc.contributor.authorDunn, Ian F.en_US
dc.contributor.authorFolkerth, Rebecca D.en_US
dc.contributor.authorSantagata, Sandroen_US
dc.contributor.authorLindeman, Neal I.en_US
dc.contributor.authorLigon, Azra H.en_US
dc.contributor.authorBeroukhim, Rameenen_US
dc.contributor.authorHornick, Jason L.en_US
dc.contributor.authorAlexander, Brian M.en_US
dc.contributor.authorLigon, Keith L.en_US
dc.contributor.authorRamkissoon, Shakti H.en_US
dc.date.accessioned2014-12-02T21:28:27Z
dc.date.issued2014en_US
dc.identifier.citationCryan, J. B., S. Haidar, L. A. Ramkissoon, W. L. Bi, D. S. Knoff, N. Schultz, M. Abedalthagafi, et al. 2014. “Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.” Oncotarget 5 (18): 8083-8092.en
dc.identifier.issn1949-2553en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:13454733
dc.description.abstractClassifying adult gliomas remains largely a histologic diagnosis based on morphology; however astrocytic, oligodendroglial and mixed lineage tumors can display overlapping histologic features. We used multiplexed exome sequencing (OncoPanel) on 108 primary or recurrent adult gliomas, comprising 65 oligodendrogliomas, 28 astrocytomas and 15 mixed oligoastrocytomas to identify lesions that could enhance lineage classification. Mutations in TP53 (20/28, 71%) and ATRX (15/28, 54%) were enriched in astrocytic tumors compared to oligodendroglial tumors of which 4/65 (6%) had mutations in TP53 and 2/65 (3%) had ATRX mutations. We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX (60%, 9/15) at frequencies similar to pure astrocytic tumors, suggesting that oligoastrocytomas and astrocytomas may represent a single genetic or biological entity. p53 protein expression correlated with mutation status and showed significant increases in astrocytomas and oligoastrocytomas compared to oligodendrogliomas, a finding that also may facilitate accurate classification. Furthermore our OncoPanel analysis revealed that 15% of IDH1/2 mutant gliomas would not be detected by traditional IDH1 (p.R132H) antibody testing, supporting the use of genomic technologies in providing clinically relevant data. In all, our results demonstrate that multiplexed exome sequencing can support evaluation and classification of adult low-grade gliomas with a single clinical test.en
dc.language.isoen_USen
dc.publisherImpact Journals LLCen
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226668/pdf/en
dash.licenseLAAen_US
dc.subjectoligodendrogliomaen
dc.subjectastrocytomaen
dc.subjectoligoastrocytomaen
dc.subjectsequencingen
dc.subjectIDHen
dc.titleClinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomasen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalOncotargeten
dash.depositing.authorSantagata, Sandroen_US
dc.date.available2014-12-02T21:28:27Z
dash.authorsorderedfalse
dash.contributor.affiliatedRamkissoon, Shakti H.
dash.contributor.affiliatedSantagata, Sandro
dash.contributor.affiliatedLigon, Keith


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record